Hugel Inc
KOSDAQ:145020
Hugel Inc
Revenue
Hugel Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Revenue
₩373B
|
CAGR 3-Years
17%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Revenue
₩3.6T
|
CAGR 3-Years
23%
|
CAGR 5-Years
26%
|
CAGR 10-Years
22%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Revenue
₩267.5B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
N
|
NatureCell Co Ltd
KOSDAQ:007390
|
Revenue
₩32.3B
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Revenue
₩350.1B
|
CAGR 3-Years
31%
|
CAGR 5-Years
33%
|
CAGR 10-Years
30%
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Revenue
₩102.9B
|
CAGR 3-Years
38%
|
CAGR 5-Years
29%
|
CAGR 10-Years
31%
|
|
Hugel Inc
Glance View
In the bustling landscape of the global biopharmaceutical market, Hugel Inc. stands out as a formidable player rooted in the dynamic world of aesthetics and medical treatments. Established in South Korea, Hugel Inc. embarked on its journey with a focus on producing botulinum toxin products, a niche that has rapidly expanded due to a surge in demand for non-surgical cosmetic procedures. The company navigated early challenges with innovative prowess, crafting a strong reputation for high-quality products that cater to a global clientele. The ethos of innovation and safety permeates its operations, enabling Hugel to diversify its portfolio and steadily gain traction in international markets, including significant footprints in Asia, Europe, and Latin America. Through a network of strategic partnerships and a robust distribution channel, Hugel not only pioneered advancements in cosmetic treatments but also cemented its status as a key contributor to the evolving aesthetics industry. The company's revenue model hinges upon the development, production, and distribution of its botulinum toxin and hyaluronic acid-based products. By focusing on research and development, Hugel enhances its capacity to innovate, delivering cutting-edge solutions that meet the rising demands of beauty-conscious consumers. Its business strategy also extends to therapeutics, exploring potential applications of its core products to address various medical conditions. Hugel's financial growth is propelled by the continuous expansion into new geographical territories and the gradual introduction of new, clinically-researched products. As the company continues to navigate the intricate regulatory landscapes of the pharmaceutical industry, it maintains an unwavering commitment to quality, ensuring that each product meets rigorous safety standards while catering to the evolving desires of its diverse customer base worldwide.
See Also
What is Hugel Inc's Revenue?
Revenue
373B
KRW
Based on the financial report for Dec 31, 2024, Hugel Inc's Revenue amounts to 373B KRW.
What is Hugel Inc's Revenue growth rate?
Revenue CAGR 5Y
13%
Over the last year, the Revenue growth was 17%. The average annual Revenue growth rates for Hugel Inc have been 17% over the past three years , 13% over the past five years .
You don't have any saved screeners yet